CLOTRIMADERM VAGINAL 6 CREAM
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
29-04-2022
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
CLOTRIMAZOLE
Tillgänglig från:
TARO PHARMACEUTICALS INC
ATC-kod:
G01AF02
INN (International namn):
CLOTRIMAZOLE
Dos:
1%
Läkemedelsform:
CREAM
Sammansättning:
CLOTRIMAZOLE 1%
Administreringssätt:
VAGINAL
Enheter i paketet:
50GM
Receptbelagda typ:
OTC
Terapiområde:
AZOLES
Produktsammanfattning:
Active ingredient group (AIG) number: 0110231001; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2020-02-21
Produktens egenskaper
_PAGE 1 OF 22_
_ _
_CLOTRIMADERM VAGINAL 6 _
_CLOTRIMADERM VAGINAL 3 _
_CLOTRIMADERM EXTERNAL CREAM _
PRODUCT
MO
N
OG
RA
PH
CLOTRIMADERM VAGINAL 6
(Clotrimazo le
Vaginal Cream USP 1%)
CLOTRIMADERM VAGINAL 3
(Clotrimazo le
Vaginal Cream USP 2%)
CLOTRIMADERM EXTERNAL C
RE
AM
(Clotrimazole
Vaginal Cream USP 1%)
ANTIFUNGAL
AG
E
NT
Taro Pharmaceuticals
Inc. Date of Revision:
130 East Drive
April 29, 2022
Brampton,
Ontario
L6T 1C1
CONTROL #263252
_PAGE 2 OF 22_
_ _
_CLOTRIMADERM VAGINAL 6 _
_CLOTRIMADERM VAGINAL 3 _
_CLOTRIMADERM EXTERNAL CREAM _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
.........................................................................................
3
CONTRAINDICATIONS
.............................................................................................................
3
WARNINGS AND
PRECAUTIONS.............................................................................................
3
ADVERSE REACTIONS
.............................................................................................................
4
DRUG INTERACTIONS
..............................................................................................................
5
DOSAGE AND
ADMINISTRATION...........................................................................................
6
OVERDOSAGE
............................................................................................................................
6
ACTION AND CLINICAL PHARMACOLOGY
......................................................................
6
STORAGE AND
STABILITY.......................................................................................................
8
DOSAGE FORMS, COMPOSITION AND PACKAGING
............................................................. 8
PART II: SCIENTIFIC INFORMATION
....
Läs hela dokumentet
